ClinicalTrials.gg
CompletedNCT00482092Updated Mar 11, 2026

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

A Phase 3 interventional study of Prochymal® and Placebo in Crohn's Disease, sponsored by Mesoblast, Inc.. Completed at 56 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Mesoblast, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2014, 12 years 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
80th of 528
330 · median 60
Started
2007
with 21 others
Phase 3
124 of 660
21 open now
Registered
85th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 80th largest by enrollment of the 528 interventional ones that give a count, is one of 22 that started in 2007, is one of 124 in phase 3, and was the 85th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

Protocol 603 is enrolling subjects with moderate-to-severe Crohn's disease who are intolerant to, or have previously failed therapy with, at least one steroid and at least one immunosuppressant and a biologic monoclonal anti-body to tumor necrosis factor alpha. The protocol investigates the safety and efficacy of using PROCHYMAL® adult human stem cells to induce remission. PROCHYMAL is delivered through a vein in the arm four times over two weeks, for approximately an hour each time.

Read the detailed description

A significant number of individuals with Crohn's disease do not find relief with existing steroidal, immunosuppressive, or biologic therapies, and are forced to seek surgery or other drastic measures for treatment.

PROCHYMAL® adult human stem cells are manufactured from healthy, volunteer donors, extensively tested, and are stored to be available as needed. Human and animal studies have shown that the cells do not require any donor-recipient matching. The cells may have both immunosuppressive and healing benefits in Crohn's disease. The cells naturally migrate specifically to sites of inflammation, so their effects are believed to be local and self-limiting rather than systemic.

Protocol 603 is enrolling subjects to evaluate the ability of PROCHYMAL to induce remission in subjects with moderate-to-severe disease (Crohn's disease activity index -- CDAI -- of between 250 and 450, inclusive) who have failed or been intolerant of at least one drug in each of the steroid, immunosuppressant, and biologic classes.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's disease
  • adult stem cell therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • failed (within last 2 yr) or intolerant of at least one AND at least one AND at EXACTLY one biologic
  • CDAI between 250 and 450, inclusive
  • endoscopically or radiographically confirmed Crohn's disease of ileus or colon or both
  • C-Reactive Protein Test (CRP) of at least 5 mg/l (0.5 mg/dl)*OR* CDAI of at least 300
  • weight between 40 and 150 kg, inclusive
  • adequate renal function
  • negative tuberculosis skin (PPD) test (or evaluated low risk of TB activation)

Exclusion criteria

Exclusion Criteria:

  • or hepatitis infection active
  • allergy to CT contrast agents, or to bovine or porcine products
  • symptomatic fibrostenotic Crohn's disease
  • permanent ostomy
  • biologic therapy within past 90 d
  • prednisone greater than 20 mg/d within past month
  • short-bowel syndrome
  • total parenteral nutrition
  • abnormal liver function
  • active within past 5 years (except completely resected basal or squamous cell carcinoma of skin)
  • enteric pathogens, including C. difficile
  • history of colonic mucosal dysplasia
  • current or prior evidence of tuberculosis (TB) (unless risk of activation or re-activation deemed low)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive matching placebo administered as intravenous (IV) infusions.

    Drug: Placebo

  • Active comparator
    Prochymal® - Low dose

    Participants will receive a total dose of Prochymal® 600 x 10\^6 cells, IV infusion, on four days, once daily.

    Drug: Prochymal®

  • Active comparator
    Prochymal® - High dose

    Participants will receive a total dose of Prochymal® 1200 x 10\^6 cells, IV infusion, on four days, once daily.

    Drug: Prochymal®

Interventions

  • Prochymal® IV infusion

    Also known as: Adult Human Mesenchymal Stem Cells

  • DrugPlacebo

    Prochymal® Placebo-matching IV infusion

06

What researchers measure

Primary outcomes

  1. Disease remission (CDAI at or below 150)

    Time frame: 28 days

Secondary outcomes

  1. Disease improvement (Reduction by at least 100 points in CDAI)

    Time frame: 28 days

  2. Improvement in quality of life (IBDQ)

    Time frame: 28 days

  3. Reduction in number of draining fistulas

    Time frame: 28 days

07

Study locations

56 sites
  • University of Southern California University Hospital
    Los Angeles, California 90033, United States
  • University of California, San Francisco
    San Francisco, California 94115, United States
  • Western States Clinical Research
    Wheat Ridge, Colorado 80033, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Borland-Groover Clinic
    Jacksonville, Florida 32256, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Carle Clinic Association
    Urbana, Illinois 61801, United States
  • Indiana University Medical Center
    Indianapolis, Indiana 46202, United States
  • Cotton-O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • University of Kentucky Hospital
    Lexington, Kentucky 40536, United States
  • University of Louisville Hospital
    Louisville, Kentucky 40202, United States
  • Gulf Coast Research
    Baton Rouge, Louisiana 70808, United States
  • University of Maryland, Baltimore
    Baltimore, Maryland 21201, United States
  • National Institutes of Health
    Bethesda, Maryland 20892, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Center for Clinical Studies
    Dearborn, Michigan 48124, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • University of Minnesota Hospital
    Minneapolis, Minnesota 55455, United States
  • St Louis Center for Clinical Studies
    St Louis, Missouri 63128, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Weill Cornell Medical College
    New York, New York 10028, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Rochester Institute for Digestive Diseases
    Rochester, New York 14607, United States
  • Rochester General Hospital
    Rochester, New York 14621, United States
  • University Hospital and Medical Center
    Stony Brook, New York 11794, United States
  • Charlotte Gastroenterology and Hepatology
    Charlotte, North Carolina 28207, United States
  • Pinehurst Medical Clinic
    Pinehurst, North Carolina 28734, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • Gastroenterology United of Tulsa
    Tulsa, Oklahoma 74135, United States
  • Options Health Research
    Tulsa, Oklahoma 74137, United States
  • Allegheney Center for Digestive Health
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Gastroenterology Center of the Midsouth
    Germantown, Tennessee 37138, United States
  • Nashville GI Specialists
    Nashville, Tennessee 37205, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
  • University of Texas Health Science Center
    Houston, Texas 77030, United States
  • University of Vermont
    Burlington, Vermont 05401, United States
  • Digestive and Liver Disease Specialists
    Norfolk, Virginia 23502, United States
  • McGuire Research Institute
    Richmond, Virginia 23249, United States
  • Seattle Gastroenterology Associates
    Seattle, Washington 98133, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria, Australia
  • University of Calgary
    Calgary, Alberta T2N 4N1, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2X8, Canada
  • Health Science Centre
    Winnipeg, Manitoba R3A 1R9, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • Mount Sinai Hospital
    Toronto, Ontario M5G 1X5, Canada
  • University of Otago
    Christchurch, New Zealand
  • Waikato Hospital
    Hamilton, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2007 to primary completion in Sep 2014, 83 months.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 83 months is above that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2007
First posted
Jun 4, 2007
StartActual
Sep 17, 2007
Primary completionActual
Sep 15, 2014
CompletionActual
Sep 15, 2014
Results delay requested
Dec 20, 2021
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00482092
Lead sponsor
Mesoblast, Inc.
Responsible party
Sponsor
First posted
Jun 4, 2007
Start date
Sep 17, 2007
Primary completion
Sep 15, 2014
Completion
Sep 15, 2014
Last update
Mar 11, 2026

Study contacts

Mahboob Rahman, MD
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion